secukinumab 300 mg Q4W + secukinumab 300 mg Q2W
Phase 2CompletedDevelopment Stage
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Jul 27, 2020 → May 3, 2022
About secukinumab 300 mg Q4W + secukinumab 300 mg Q2W
secukinumab 300 mg Q4W + secukinumab 300 mg Q2W is a phase 2 stage product being developed by Novartis for Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris. The current trial status is completed. This product is registered under clinical trial identifier NCT04300296. Target conditions include Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris.
What happened to similar drugs?
0 of 2 similar drugs in Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04300296 | Phase 2 | Completed |
Competing Products
12 competing products in Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LP-10 (Liposomal Tacrolimus) | Lipella Pharmaceuticals | Phase 2 | 29 |
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 35 |
| Baricitinib 4 milligram Oral Tablet | Eli Lilly | Phase 2 | 39 |
| pimecrolimus and clobetasol + clobetasol 0.05% cream | Novartis | Phase 2 | 35 |
| Pimecrolimus 1% cream | Novartis | Phase 2 | 35 |
| Apremilast + Placebo | Amgen | Phase 2 | 31 |
| Deucravacitinib | Bristol Myers Squibb | Phase 2 | 35 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 44 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 44 |
| Amevive (Alefacept) + Placebo | Biogen | Phase 2 | 24 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 32 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 32 |